Business
Study shows patients treated with Smith+Nephe...
Study shows patients treated with Smith+Nephe....
About this update from Smith & Nephew Plc
[{"type":"text","content":"\n\n \n \n\n Study shows patients treated with Smith+Nephew’s CARTIHEAL™ AGILI-C™ Cartilage Repair Implant have an 87% lower relative risk of Total Knee Arthroplasty or Osteotomy at 4 years¹*\n\nThe CARTIHEAL Implant will be featured at the Arthroscopy Association of North America Annual Meeting (AANA 2025) this week Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces encouraging results for its CARTIHEAL AGILI-C Cartilage Repair Implant from a recent multicentre randomised controlled trial (RCT) treating knee cartilage defects. When compared to the current surgical standard of care,* the implant demonstrated: Superior pain relief: Patients treated with the CARTIHEAL AGILI-C Implant reported significantly better knee pain relief, and quality of life improvements over a 4-year period.1-3 ** Superior functional gains: Patients treated with the CARTIHEAL Implant reported superior improvements in performing activities related to daily living, sport and recreation at 2 and 4 years. 1-3 Different patient profiles – same great results: The scaffold effectively treated a broad group of patients across age, lesion size, and presence of osteoarthritis while delivering clinically meaningful results.1-3 ** Smith+Nephew's FDA-approved CARTIHEAL Implant, which previously received breakthrough designation, is revolutionizing the cartilage repair landscape. In line with AANA's mission to improve patient outcomes through education and innovation, the implant’s broad indication allows physicians to treat patients who previously may not have had access. Professor Elizaveta Kon from Humanitas Research Hospital, who plans to present 4-year outcomes of the implant with respect to gender during AANA 2025, highlighted the importance of inclusivity in study design. “We need a technology that we can trust to work in the patients we see day-to-day. This is where CARTIHEAL has excelled, showcasing superior performance across genders, lesion location, and more.” Dr. Vinod Dasa of Louisiana State University School of Medicine finds the technology particularly meaningful for his patients. \"The patients that come to see me are looking for a bridging procedure that enables them to continue their day-to-day life, playing with their kids and grandkids. In addition to the pain relief and functional gains,...